Scientists Engineer T Cells That Attack Both Tumors and the Immune Cells Protecting Them

Most cancer immunotherapies aim squarely at the tumor. A new study published in Signal Transduction and Targeted Therapy suggests a more ambitious strategy: engineering T cells that can simultaneously attack cancer cells and the immunosuppressive immune cells that protect them. The research is early-stage, built entirely on laboratory experiments, but the underlying concept could shift how researchers think about dismantling the tumor microenvironment.

PDL101-TCR-T Cells Kill Tumors and Their Immune Shields

The target is PD-L1, a protein best known as the "don't eat me" signal that tumors exploit to switch off immune attacks. Rather than simply blocking PD-L1 with an antibody, as checkpoint inhibitors do, the team reconstructed a naturally occurring T-cell receptor, called PDL101-TCR, that physically recognizes a specific fragment of the PD-L1 protein presented on the cell surface. They then introduced this receptor into primary CD8+ T cells from seven healthy donors, replacing the cells' original receptor in the process. The result was a T cell engineered to seek and destroy any cell displaying PD-L1, whether that cell is a cancer cell or an immune cell co-opted into suppressing the anti-tumor response.

The engineered cells performed well in initial tests. PDL101-TCR-T cells produced IFN-γ and TNF-α, two hallmark cytokines of an active immune response, and upregulated CD107a, a marker of degranulation that indicates a T cell is actively killing. Against peptide-loaded target cells, cytotoxicity was measurable down to the low picomolar range of antigen concentration, a sign of high sensitivity.

Immunosuppressive Myeloid Cells Are Also Viable Targets

Beyond tumor cells, one of the study's more striking findings involves myeloid cells: immune cells that tumors can recruit and reprogram into suppressors. The researchers differentiated myeloid cells into two phenotypes commonly found in tumors, tumor-associated macrophage-like (TAM-like) cells and myeloid-derived suppressor/M2-like (MDSC/M2-like) cells. Both showed elevated PD-L1 expression, and both triggered statistically significant responses from the PDL101-TCR-T cells. The response against MDSC/M2-like cells was particularly robust, possibly because those cells also expressed higher levels of CD86, a co-stimulatory molecule that amplifies T-cell activation.

This dual targeting matters because suppressive myeloid cells are a major reason checkpoint blockade and other immunotherapies often fall short. Removing them, rather than simply neutralizing their signals with antibodies, could allow the broader immune response to operate more freely inside the tumor. A clinical trial combining PD-L1-derived peptide vaccination with PD-1 blockade in metastatic melanoma patients has already shown encouraging response rates using a related concept, lending some translational context to the approach.

Non-Viral CRISPR-Cas9 Editing Enables Precise TCR Integration

The method the team used to build these cells is itself noteworthy. Instead of viral vectors, which carry manufacturing and regulatory complications, the researchers used non-viral CRISPR-Cas9 editing to slot the PDL101-TCR gene into the TRAC locus of primary CD8+ T cells. They simultaneously knocked out the endogenous T-cell receptor beta constant (TRBC) loci to prevent mispairing between the introduced receptor and remnants of the original one. After editing, they confirmed successful integration and expanded the engineered population using PDL101-loaded HLA-A2 tetramers, achieving a 5 to 6-fold expansion that brought PDL101-TCR-positive cells to 50 to 65 percent of the culture. The use of a physiological, MHC-restricted TCR, rather than a synthetic chimeric antigen receptor, is also notable: TCR-based approaches are thought to carry an intrinsic safety advantage because they depend on normal antigen presentation machinery, which may reduce the risk of off-target toxicity compared to CAR-T cell therapies that bypass that machinery entirely.

As Thomas Hvidkjær Lisle, one of the study's authors, put it: "After many experiments and years of work, we can now report the successful generation of TCR-T cells recognizing a PD-L1-derived antigen. Importantly, these PD-L1-specific TCR-T cells can recognize both tumor cells and immune cells expressing PD-L1, potentially enabling a broader attack on the immunosuppressive tumor microenvironment."

Open Questions About Tolerogenic DCs and On-Target Toxicity

The study is explicit about its limits. Everything reported is in vitro; no animal models have been tested yet. CRISPR-Cas9 editing also yielded lower integration and expression rates for PDL101-TCR compared to viral transduction methods, a practical hurdle for manufacturing at scale. There is also a conceptual tension at the heart of the approach: PD-L1 is expressed on dendritic cells, including the tolerogenic ones the therapy is designed to eliminate, but also on healthy antigen-presenting cells that the immune system genuinely needs. Depleting those cells could theoretically blunt the very immune response the therapy is trying to amplify. The methodological challenges inherent to novel cellular therapies like this one, including off-tumor toxicity and scalable manufacturing, are well-documented in the field and remain squarely unresolved here.

The addition of anti-PD-1 treatment during co-culture showed only variable, modest increases in IFN-γ secretion, suggesting that combining this TCR approach with existing checkpoint inhibitors may not produce straightforward synergy. How the cells would behave in an actual tumor microenvironment, with its complex mix of signals, hypoxia, and competing cell populations, is an open question.

Preclinical Testing in Animal Models Is the Immediate Next Step

The authors frame the work as proof-of-concept, warranting further preclinical investigation before any clinical translation. That means animal studies testing whether PDL101-TCR-T cells can reduce tumor burden in vivo, and whether systemic PD-L1 targeting produces manageable side effects. The broader field is already grappling with how to measure the real-world impact of early-stage immunotherapy research and set realistic expectations for translation timelines. If preclinical data hold up, the non-viral CRISPR manufacturing approach could support a pathway toward clinical-grade production that avoids some of the regulatory friction associated with viral vectors. The intersection of adoptive cell therapy and checkpoint biology is an active area, and this study adds a technically distinct approach to a crowded field. For now, the headline is cautious but genuine: a T cell that can see through PD-L1's disguise and eliminate both the tumor and its defenders has been built and tested in a dish.

Evidence rating

INVESTIGATIONAL — 57/100

In vitro proof-of-concept letter using primary CD8+ T cells from seven healthy donors. All findings are cell-culture based, with no in vivo or clinical validation; results cannot establish causation or predict clinical outcomes. Not yet replicated in independent preclinical or human studies.

References

1. Thomas Landkildehus Lisle, Emilie Bülow Jacobsen, Shamaila Munir Ahmad, Özcan Met, Rasmus O. Bak, Mads Hald Andersen (2026). Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-026-02798-y
2. Benedikt Fecher, Freia Kuper, Nataliia Sokolovska, Alex Fenton, Stefan Hornbostel, Gert G. Wagner (2021). Understanding the Societal Impact of the Social Sciences and Humanities: Remarks on Roles, Challenges, and Expectations. Frontiers in Research Metrics and Analytics. https://doi.org/10.3389/frma.2021.696804
3. Strategies to address the methodological challenges of client-satisfaction research in home care – PubMed. NIH. https://pubmed.ncbi.nlm.nih.gov/9355291/
4. Measuring the societal impact of research – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656729/